Relapsed or Refractory Myelodysplastic Syndrome Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023

DelveInsight's, "Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Relapsed or Refractory Myelodysplastic Syndrome pipeline landscape. It covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsed or Refractory Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Relapsed or Refractory Myelodysplastic Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Relapsed or Refractory Myelodysplastic Syndrome treatment.
• The leading companies working in the Relapsed or Refractory Myelodysplastic Syndrome Market include Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and others.
• Promising Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies in the various stages of development include CX-01, Azacitidine, SyB C-1101, NC525, LP-108, CC-91633, Talacotuzumab, Daratumumab, CC-90009, BTX-A51, and others.
• November 2023: NextCure Inc. announced a study of Phase 1 clinical trials for NC525. This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms. A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms.
• October 2023: Celgene announced a study of Phase 1 clinical trials for CC-91633. A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes.Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
• October 2023: Thomas Jefferson University announced a study of Phase 1 & 2 clinical trials for Venetoclax and Decitabine. This phase Ib/II trial tests the safety, side effects, and best dose of navitoclax in combination with venetoclax and decitabine in treating patients with higher risk myelodysplastic syndrome (MDS) that has come back after initial treatment or was not responsive to initial treatment. This study will also look at the effectiveness of the treatment combination and patient's quality of life while on these medications. Navitoclax is an oral drug that works as an inhibitor of the BCL-2 family of proteins, which are often overly expressed in a wide variety of cancers and are linked to tumor drug resistance. This drug blocks some of the enzymes that keep cancer cells from dying. Venetoclax is an oral drug that works as an inhibitor of BCL-2 proteins that works very similarly to navitoclax by blocking the action of a certain proteins in the body that helps cancer cells survive which helps to kill cancer cells.
• October 2023: M.D. Anderson Cancer Center announced a study of Phase 1 & 2 clinical trials for Akt/ERK Inhibitor ONC201. This phase I/II trial studies the side effects and best dose of ONC201 and to see how well it works in treating patients with acute leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). ONC201 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Request a sample and discover the recent advances in Relapsed or Refractory Myelodysplastic Syndrome Treatment Drugs @ Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report- https://www.delveinsight.com/report-store/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Relapsed or Refractory Myelodysplastic Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed or Refractory Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Relapsed or Refractory Myelodysplastic Syndrome Overview
Myelodysplastic syndromes (MDS) are defined by ineffective hematopoiesis resulting in blood cytopenias, and clonal instability with a risk of clonal evolution to acute myeloid leukemia (AML).Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML3.

Find out more about Relapsed or Refractory Myelodysplastic Syndrome Therapeutics Assessment @ Relapsed or Refractory Myelodysplastic Syndrome Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Relapsed or Refractory Myelodysplastic Syndrome Emerging Drugs Profile
• CX-01: Cantex Pharmaceuticals
• LP-108: Newave Pharmaceuticals
• BTX-A51: BioTheryX

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the Relapsed or Refractory Myelodysplastic Syndrome therapies. The Relapsed or Refractory Myelodysplastic Syndrome companies which have their Relapsed or Refractory Myelodysplastic Syndrome drug candidates in the mid to advanced stage, i.e. Phase II include, Cantex Pharmaceuticals and others.

DelveInsight's Relapsed or Refractory Myelodysplastic Syndrome Pipeline report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Relapsed or Refractory Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Parenteral
• Molecule Type

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Products have been categorized under various Molecule types such as
• Small molecules
• Polymer
• Peptide
• Gene Therapy
• Monoclonal antibodies
• Product Type

Learn more about the emerging Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies @ Relapsed or Refractory Myelodysplastic Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Report
• Coverage- Global
• Relapsed or Refractory Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsed or Refractory Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Relapsed or Refractory Myelodysplastic Syndrome Companies- Cantex Pharmaceuticals, Novartis, Newave Pharmaceuticals, BioTheryX, Agios Pharmaceuticals, and others.
• Relapsed or Refractory Myelodysplastic Syndrome Pipeline Therapies- CX-01, Azacitidine, SyB C-1101, NC525, LP-108, CC-91633, Talacotuzumab, Daratumumab, CC-90009, BTX-A51, and others.

Dive deep into rich insights for new drugs for Relapsed or Refractory Myelodysplastic Syndrome Treatment, Visit @ Relapsed or Refractory Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Relapsed or Refractory Myelodysplastic Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsed or Refractory Myelodysplastic Syndrome - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Relapsed or Refractory Myelodysplastic Syndrome Collaboration Deals
9. Late Stage Products (Phase III)
10. AG-120: Agios Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. CX-01: Cantex Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early-Stage Products (Phase I)
16. BTX A51: BioTheryX
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Relapsed or Refractory Myelodysplastic Syndrome Key Companies
20. Relapsed or Refractory Myelodysplastic Syndrome Key Products
21. Relapsed or Refractory Myelodysplastic Syndrome- Unmet Needs
22. Relapsed or Refractory Myelodysplastic Syndrome- Market Drivers and Barriers
23. Relapsed or Refractory Myelodysplastic Syndrome- Future Perspectives and Conclusion
24. Relapsed or Refractory Myelodysplastic Syndrome Analyst Views
25. Relapsed or Refractory Myelodysplastic Syndrome Key Companies
26. Appendix

For further information on the Relapsed or Refractory Myelodysplastic Syndrome Pipeline therapeutics, reach out to Relapsed or Refractory Myelodysplastic Syndrome Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/relapsed-or-refractory-myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Important Published Links

https://logcworld.mn.co/posts/46134506
https://marketingops.mn.co/posts/46134636
https://motorcycle-events.mn.co/posts/46134899
https://intuitive-schooling.mn.co/posts/46135011
https://plenty-of-heathens.mn.co/posts/advancements-and-market-trends-in-langerhans-cell-histiocytosis-treatment
https://shopsanity.mn.co/posts/understanding-the-langerhans-cell-histiocytosis-market-current-landscape-and-future-prospects
https://mccoterie.mn.co/posts/46135751
https://go02100.mn.co/posts/46136119
https://freesaloneducation.mn.co/posts/46136215
https://sokomtaani.mn.co/posts/46136615
https://skillcrush.mn.co/posts/46136691
https://advicehonest.mn.co/posts/46136795
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.